Aerie Pharmaceuticals drew an early approval from the FDA for its eye drop, Rhopressa.
The product, intended as a treatment for glaucoma, received clearance two months ahead of the expected date. It was previously delayed after the company submitted its application in 2016 because of problems at the Florida facility where it was produced.
The approval follows a 9-1 advisory committee vote recommending the drug. The drug reduces pressure on the eye’s trabecular meshwork through which fluid flows.